Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma)

Pancreas

Volumn 42, Issue 2, 2013, Pages 348-352

  Bourcier, Matthew E ^a   Vinik, Aaron I ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

neuroendocrine tumor; paraganglioma; sunitinib; vasoactive intestinal peptideoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ALISKIREN; ANGIOPEPTIN; CALCITONIN; CAPECITABINE; CARVEDILOL; CLONIDINE; ERGOCALCIFEROL; GASTRIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; METIROSINE; OCTREOTIDE; OLMESARTAN; PANCREASTATIN; PENTETREOTIDE; PHENOXYBENZAMINE; SOMATOSTATIN RECEPTOR; SUNITINIB; TEMOZOLOMIDE; TESTOSTERONE; VASOACTIVE INTESTINAL POLYPEPTIDE; VERAPAMIL;

AGED; ANTIANGIOGENIC THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; CASE REPORT; CHILD; CHOLECYSTECTOMY; CHOLELITHIASIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FLUSHING; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGONADISM; INTESTINE OBSTRUCTION; LIVER BIOPSY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT CARE; PANCREAS RESECTION; PARAGANGLIOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SCHOOL CHILD; SIDE EFFECT; VIPOMA;

ABDOMINAL NEOPLASMS; AGED; ANTINEOPLASTIC AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; PANCREATIC NEOPLASMS; PARAGANGLIOMA; PROTEIN KINASE INHIBITORS; PYRROLES; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VIPOMA;

EID: 84874058676     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31825c53fa     Document Type: Article

References (33)

1. Halfdanarson TR, Rubin J, Farnell MB, et al. Pancreatic endocrine neoplasms: Epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer. 2008;15:409-427.
2. Vemer IV, Morrison AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med. 1958;25:374-380.
3. Said SI, Mutt V. Polypeptide with broad biological activity. Isolation from small intestine. Science. 1970;169:1217-1218.
4. Mekhjian HS, O'Dorisio TM. VIPoma syndrome. Semin Oncol. 1987;14:282-291.
5. Vinik AI, Woltering EA, Warner RR, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39:713-734.
6. Chen H, Sippel RS, O'Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: Pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39:775-783.
7. Raymond E, Dahan L, Raoul J-L, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501-513.
8. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-523.
9. Tsai ST, Brunner SF, Vinik AI. Management of refractory diarrhea using a somatostatin analogue (SMS201-995). Diabetes. 1986;35(suppl 1): Abstract 141A.
10. Vinik AI, Tsai ST, Moattari AR, et al. Somatostatin analogue (SMS201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes. Am J Med. 1986;81:23-40.
11. Rosenberg L, Dafoe DC, Schwartz R, et al. Administration of somatostatin analogue (SMS201-995) in the treatment of a fistula occurring after pancreas transplantation. Interference with cyclosporine immunosuppression. Transplantation. 1987;43:764-766.
12. Turner GB, Johnston BT, McCance DR, et al. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut. 2006;55:1586-1591.
13. Rindi G, Klo?ppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch. 2006;449:395-401.
14. Pape UF, Jann H, Mu?ller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008;113:256-265.
15. Vinik E, Carlton CA, Silva MO, et al. Development of the Norfolk quality of life tool for assessing patients with neuroendocrine tumors. Pancreas. 2009;38:87-95.
16. Bloomston M, Al-Saif O, Klemanski D, et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: Lessons learned. J Gastrointest Surg. 2007;11:264-271.
17. O'Dorisio TM, Krutzik SR, Woltering EA, et al. Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behaviour. Pancreas. 2010;39:611-616.
18. Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39:735-752.
19. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer. 2004;11:1-18.
20. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327-337.
21. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2:471-478.
22. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101:3597-3605.
23. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 2003;20:757-766.
24. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab. 2006;91:4070-4076.
25. Kodera Y, Katanasaka Y, Kitamura Y, et al. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res. 2011;13:R66.
26. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose Wchemo-switchW regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol. 2005;23:939-952.
27. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25-35.
28. Kulke M, Lenz HJ, Meropol N, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403-3410.
29. Vinik A, Bang J, Raoul J-L, et al. Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial. J Clin Oncol. 2010; 28(suppl); abstract 4003.
30. Starker LF, Carling T. Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Curr Opin Oncol. 2009;21:29-33.
31. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331:1199-1203.
32. Vinik AI, Anthony L, Boudreaux JP, et al. Neuroendocrine tumors: A critical appraisal of management strategies. Pancreas. 2010;39:801-818.
33. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663.